These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30002125)

  • 1. The
    Ka C; Guellec J; Pepermans X; Kannengiesser C; Ged C; Wuyts W; Cassiman D; de Ledinghen V; Varet B; de Kerguenec C; Oudin C; Gourlaouen I; Lefebvre T; Férec C; Callebaut I; Le Gac G
    Haematologica; 2018 Nov; 103(11):1796-1805. PubMed ID: 30002125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China.
    Zhang W; Xu A; Li Y; Zhao S; Zhou D; Wu L; Zhang B; Zhao X; Wang Y; Wang X; Duan W; Wang Q; Nan Y; You H; Jia J; Ou X; Huang J;
    Liver Int; 2019 Jun; 39(6):1120-1127. PubMed ID: 30500107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual loss and gain of function of the FPN1 iron exporter results in the ferroportin disease phenotype.
    Uguen K; Le Tertre M; Tchernitchko D; Elbahnsi A; Maestri S; Gourlaouen I; Férec C; Ka C; Callebaut I; Le Gac G
    HGG Adv; 2024 Oct; 5(4):100335. PubMed ID: 39039793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron.
    Koyama C; Wakusawa S; Hayashi H; Ueno T; Suzuki R; Yano M; Saito H; Okazaki T
    Intern Med; 2005 Sep; 44(9):990-3. PubMed ID: 16258219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients.
    Callebaut I; Joubrel R; Pissard S; Kannengiesser C; Gérolami V; Ged C; Cadet E; Cartault F; Ka C; Gourlaouen I; Gourhant L; Oudin C; Goossens M; Grandchamp B; De Verneuil H; Rochette J; Férec C; Le Gac G
    Hum Mol Genet; 2014 Sep; 23(17):4479-90. PubMed ID: 24714983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of three novel pathogenic SLC40A1 mutations and genotype/phenotype correlations in 7 Italian families with type 4 hereditary hemochromatosis.
    Majore S; Bonaccorsi di Patti MC; Valiante M; Polticelli F; Cortese A; Di Bartolomeo S; De Bernardo C; De Muro M; Faienza F; Radio FC; Grammatico P; Musci G
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):464-470. PubMed ID: 29154924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.
    Mayr R; Janecke AR; Schranz M; Griffiths WJ; Vogel W; Pietrangelo A; Zoller H
    J Hepatol; 2010 Nov; 53(5):941-9. PubMed ID: 20691492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.
    Griffiths WJ; Mayr R; McFarlane I; Hermann M; Halsall DJ; Zoller H; Cox TM
    Hepatology; 2010 Mar; 51(3):788-95. PubMed ID: 19937651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man.
    Del-Castillo-Rueda A; Moreno-Carralero MI; Alvarez-Sala-Walther LA; Cuadrado-Grande N; Enríquez-de-Salamanca R; Méndez M; Morán-Jiménez MJ
    Eur J Haematol; 2011 Mar; 86(3):260-4. PubMed ID: 21175851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
    Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
    Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
    Le Tertre M; Ka C; Guellec J; Gourlaouen I; Férec C; Callebaut I; Le Gac G
    Transfus Clin Biol; 2017 Nov; 24(4):462-467. PubMed ID: 28826751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.
    Speletas M; Kioumi A; Loules G; Hytiroglou P; Tsitouridis J; Christakis J; Germenis AE
    Blood Cells Mol Dis; 2008; 40(3):353-9. PubMed ID: 17997113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain.
    Bach V; Remacha A; Altés A; Barceló MJ; Molina MA; Baiget M
    Blood Cells Mol Dis; 2006; 36(1):41-5. PubMed ID: 16257244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro.
    Moreno-Carralero MI; Muñoz-Muñoz JA; Cuadrado-Grande N; López-Rodríguez R; José Hernández-Alfaro M; del-Castillo-Rueda A; Enríquez-de-Salamanca R; Méndez M; Morán-Jiménez MJ
    Am J Hematol; 2014 Jul; 89(7):689-94. PubMed ID: 24644245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues.
    Le Gac G; Ka C; Joubrel R; Gourlaouen I; Lehn P; Mornon JP; Férec C; Callebaut I
    Hum Mutat; 2013 Oct; 34(10):1371-80. PubMed ID: 23784628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and clinical heterogeneity of ferroportin disease.
    Cremonesi L; Forni GL; Soriani N; Lamagna M; Fermo I; Daraio F; Galli A; Pietra D; Malcovati L; Ferrari M; Camaschella C; Cazzola M
    Br J Haematol; 2005 Dec; 131(5):663-70. PubMed ID: 16351644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular model of the ferroportin intracellular gate and implications for the human iron transport cycle and hemochromatosis type 4A.
    Guellec J; Elbahnsi A; Tertre ML; Uguen K; Gourlaouen I; Férec C; Ka C; Callebaut I; Gac GL
    FASEB J; 2019 Dec; 33(12):14625-14635. PubMed ID: 31690120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
    Viveiros A; Panzer M; Baumgartner N; Schaefer B; Finkenstedt A; Henninger B; Theurl I; Nachbaur K; Weiss G; Haubner R; Decristoforo C; Tilg H; Zoller H
    Liver Int; 2020 Aug; 40(8):1941-1951. PubMed ID: 32450003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 4B hereditary hemochromatosis due to heterozygous p.D157A mutation in SLC40A1 complicated with hypopituitarism.
    Honma Y; Karasuyama T; Kumamoto K; Shimajiri S; Toki Y; Tatsumi Y; Sumida K; Koikawa K; Morino K; Oe S; Miyagawa K; Yamasaki M; Shibata M; Abe S; Ikuta K; Hayashi H; Harada M
    Med Mol Morphol; 2021 Mar; 54(1):60-67. PubMed ID: 32607777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis.
    Morris TJ; Litvinova MM; Ralston D; Mattman A; Holmes D; Lockitch G
    Blood Cells Mol Dis; 2005; 35(3):309-14. PubMed ID: 16111902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.